Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV000567505 | SCV000675702 | uncertain significance | Hereditary cancer-predisposing syndrome | 2021-05-13 | criteria provided, single submitter | clinical testing | The p.N1681D variant (also known as c.5041A>G), located in coding exon 38 of the TSC2 gene, results from an A to G substitution at nucleotide position 5041. The asparagine at codon 1681 is replaced by aspartic acid, an amino acid with highly similar properties. This amino acid position is highly conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Labcorp Genetics |
RCV001065808 | SCV001230792 | benign | Tuberous sclerosis 2 | 2024-01-07 | criteria provided, single submitter | clinical testing | |
Gene |
RCV001764691 | SCV002000658 | uncertain significance | not provided | 2021-04-26 | criteria provided, single submitter | clinical testing | In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |
Genome- |
RCV001065808 | SCV002040866 | uncertain significance | Tuberous sclerosis 2 | 2021-11-07 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV003465277 | SCV004206846 | uncertain significance | Isolated focal cortical dysplasia type II | 2023-09-13 | criteria provided, single submitter | clinical testing |